구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
GIP/GLP-1 dual agonist. SURPASS·SURMOUNT. Semaglutide 대비 체중 감소 폭과 GI AE, 적응증 확장이 경쟁 축.
Dual GIP/GLP-1 receptor agonist (Mounjaro/Zepbound) for T2D and obesity; SURPASS/SURMOUNT efficacy leader in class.
기전. Tirzepatide is a 39-amino-acid peptide activating both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting weight loss via combined incretin effects.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
GLP-1 / GIP receptor
Type 2 diabetes, chronic weight management
Global
Approved
tirzepatide · Mounjaro / Zepbound · Mounjaro · Zepbound · LY3298176 · GIP/GLP-1
2026-09-10
Data Confidence · High
Development Signal · Established
Dual incretin agonist (peptide)
39-amino acid peptide activating both GIPR and GLP-1R
Dual incretin mechanism vs GLP-1-only agonists
구조화 데이터
Dual incretin mechanism vs GLP-1-only agonists
GI side effects during titration; individualized dose escalation required.
Dual incretin agonist (peptide)
GLP-1 / GIP receptor · HbA1c, body weight, lipids.
Tirzepatide is a 39-amino-acid peptide activating both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting weight loss via combined incretin effects.
macrophages or reprogrammed (CAR) T cells may accelerate repair through hepatic stellate cell deactivation
apoptosis, and, in some studies, ferroptosis
HbA1c, body weight, lipids.
GI side effects during titration; individualized dose escalation required.
구조화 데이터
mouse
5
HbA1c ↓2.0%+; weight ↓~20% at highest dose (SURMOUNT-1)
구조화 데이터
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (T2D Mounjaro)
APPROVAL · 2022년 5월
Zepbound obesity label
APPROVAL · 2023년 11월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
GIP/GLP-1 dual agonist. SURPASS·SURMOUNT. Semaglutide 대비 체중 감소 폭과 GI AE, 적응증 확장이 경쟁 축.
Dual GIP/GLP-1 receptor agonist (Mounjaro/Zepbound) for T2D and obesity; SURPASS/SURMOUNT efficacy leader in class.
기전. Tirzepatide is a 39-amino-acid peptide activating both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting weight loss via combined incretin effects.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
GLP-1 / GIP receptor
Type 2 diabetes, chronic weight management
Global
Approved
tirzepatide · Mounjaro / Zepbound · Mounjaro · Zepbound · LY3298176 · GIP/GLP-1
2026-09-10
Data Confidence · High
Development Signal · Established
Dual incretin agonist (peptide)
39-amino acid peptide activating both GIPR and GLP-1R
Dual incretin mechanism vs GLP-1-only agonists
구조화 데이터
Dual incretin mechanism vs GLP-1-only agonists
GI side effects during titration; individualized dose escalation required.
Dual incretin agonist (peptide)
GLP-1 / GIP receptor · HbA1c, body weight, lipids.
Tirzepatide is a 39-amino-acid peptide activating both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting weight loss via combined incretin effects.
macrophages or reprogrammed (CAR) T cells may accelerate repair through hepatic stellate cell deactivation
apoptosis, and, in some studies, ferroptosis
HbA1c, body weight, lipids.
GI side effects during titration; individualized dose escalation required.
구조화 데이터
mouse
5
HbA1c ↓2.0%+; weight ↓~20% at highest dose (SURMOUNT-1)
구조화 데이터
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (T2D Mounjaro)
APPROVAL · 2022년 5월
Zepbound obesity label
APPROVAL · 2023년 11월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.